• Assess changes in financial toxicity and unmet HRSNs while using CRx-Can
• Assess patient and provider attitudes regarding facilitators and barriers to implementation of CRx-Can, including acceptability, adoption, and appropriateness

**Contact:** Cary Gross, MD • 203-737-7624 • cary.gross@yale.edu

**ClinicalTrials.gov Identifier:** N/A (Quality Pilot/Developmental Project)

---

**ERRATUM**

**Erratum to: Reimagining Cancer Staging in the Era of Evolutionary Oncology**


Dr. Zahid’s name should have been printed as “Mohammad U. Zahid, PhD.”

This has been corrected online. The authors and editors apologize for the error.

*doi: 10.6004/jnccn.2023.0018*